OPERATION: SINKING SHIP
FOCUS ON HUNTINGDON LIFE SCIENCES CUSTOMER 
When you visit the website of Bristol-Myers Squibb or BMS, it is hard to get past the legal issues as the are the very first thing highlighted on their homepage is: "Agreement With The U.S. Attorney's Office in New Jersey Deferred Prosecution Agreement (pdf)".
You can find a copy of this agreement at: http://www.bms.com/pdf/dpa.pdf
On May 2, 2006, according to industry journal "Medpage Today", Bristol-Myers Squibb "..... will no longer manufacture or sell Tequin (gatafloxacin), an antibiotic that has been linked to both hyperglycemia and hypoglycemia in diabetics and elderly patients. The company is not, however, pulling Tequin from pharmacy shelves." ( http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/3212 )
It is ironic that an activist can spraypaint graffitti on a pharmaceutical executive's garage door and be sentenced to up to 10 years in prison and labeled a "terrorist". At the same time, that very same executive might be guilty of swindling investors or customers out of massive amounts of money or continuing to sell harmful drugs to unsuspecting consumers and they face "deferred prosecution".
Add to that, their complicity in the killing of 500 animals every day by their continued customer relationship with Huntingdon Life Sciences (HLS). HLS may be doing the actual killing of those 500 animals a day, but companies like BMS are signing the contracts and cutting the checks that allow the killing to continue. Please contact Bristol-Myers Squibb's executive management team and ask them to cut their ties to HLS today.
James Cornelius
Chief Executive Officer
Bristol-Myers Squibb
345 Park Avenue
New York, NY 10154
212-546-4000
http://www.bms.com
Global Sales: $19.2 Billion
Executive Committee
James D. Robinson, III, Chairman of the Board of Directors
james.robinson@bms.com
James Cornelius, Chief Executive Officer
jim.cornelius@bms.com
Lamberto Andreotti, Executive Vice President & President Worldwide Pharmaceuticals
lamberto.andreotti@bms.com
Stephen E. Bear, Senior Vice President - Human Resources
stephen.bear@bms.com
Andrew G. Bodnar, Senior Vice President - Strategy and Medical and External Affairs
andrew.bodnar@bms.com
Andrew R. J. Bonfield, Chief Financial Officer
andrew.bonfield@bms.com
John E. Celentano, President - Health Care Group
john.celentano@bms.com
Carlo deNotaristifani, President - Technical Operations
carlo.denotaristifani@bms.com
Wendy L. Dixon, President - Global Marketing
wendy.dixon@bms.com
Anthony C. Hooper, President - U.S. Pharmaceuticals
anthony.hooper@bms.com
Tamar D. Howson, Senior Vice President - Corporate and Business Development
tamar.howson@bms.com
John L. McGoldrick, Executive Vice President and General Counsel
john.mcgoldrick@bms.com
Susan O'Day, Chief Information Officer
susan.oday@bms.com
Elliott Sigal, Chief Scientific Officer
elliot.sigal@bms.com
Jonathan K. Sprole, Chief Compliance Officer
jonathan.sprole@bms.com
Richard K. Willard, Senior Vice President and General Counsel
richard.willard@bms.com
Richard L. Wolgemuth, Senior Vice President - Global Regulatory Sciences
richard.wolgemuth@bms.com
David L. Zabor, Vice President, Strategic Business Initiatives
david.zabor@bms.com
Robert T. Zito, Senior Vice President and Chief Communications Officer
robert.zito@bms.com
All e-mails in this action alert:
james.robinson@bms.com , jim.cornelius@bms.com , lamberto.andreotti@bms.com , stephen.bear@bms.com ,
andrew.bodnar@bms.com , andrew.bonfield@bms.com , john.celentano@bms.com ,
carlo.denotaristifani@bms.com , wendy.dixon@bms.com , anthony.hooper@bms.com
tamar.howson@bms.com , john.mcgoldrick@bms.com , susan.oday@bms.com ,
elliot.sigal@bms.com , jonathan.sprole@bms.com , richard.willard@bms.com ,
richard.wolgemuth@bms.com , david.zabor@bms.com , robert.zito@bms.com
|